论文部分内容阅读
慢性肾脏病相关性贫血是慢性肾脏病(chronic kidney disease,CKD)进展过程中形成的贫血,是CKD的重要临床表现,也是主要并发症之一。有关改善肾性贫血的新型制剂,如红细胞生成刺激因子(erythropoiesis-stimulating agents,ESAs)、促红细胞生成素受体激动剂等正在临床试验中。本文综述促进红细胞生成、改善贫血的新疗法,并讨论其治疗的主要机制和不良反应;结合患者临床需求,权衡潜在优势与治疗风险,制定相关方案指导临床治疗,纠正患者贫血,进而降低心血管事件风险,提高终末期肾病(end-stage renal disease,ESRD)患者的生活质量。
Chronic kidney disease-related anemia is anemia formed during the progression of chronic kidney disease (CKD), and is an important clinical manifestation and one of major complications of CKD. Newer agents for improving renal anemia, such as erythropoiesis-stimulating agents (ESAs), erythropoietin receptor agonists, etc., are in clinical trials. This article reviews new therapies that promote erythropoiesis and improve anemia, and discusses the main mechanisms and adverse reactions of therapies. In combination with the clinical needs of patients, the potential advantages and treatment risks are weighed and relevant guidelines are formulated to guide clinical treatment to correct patients’ anemia and then reduce cardiovascular risk Event risk and improve quality of life in patients with end-stage renal disease (ESRD).